Keywords
Endoscopy Lower GI Tract - Lower GI bleeding - GI surgery - Quality and logistical
aspects - Quality management
Introduction
Colonic diverticular bleeding (CDB) is the most common cause of acute lower gastrointestinal
bleeding (ALGIB), and its management is clinically important because severe cases
need to be treated by interventional radiology (IVR) or surgery [1]
[2]. Endoscopic therapy potentially prevents recurrence of CDB with stigmata of recent
hemorrhage (SRH)
[3]
[4]
[5]
. Among the various endoscopic therapies for CDB, the clipping technique is commonly
used worldwide because of its simplicity, low cost, and theoretical advantage of causing
less damage to adjacent tissues [6]
[7]
[8]
[9]
[10]
[11]. Clipping methods for CDB are classified as direct or indirect [7]
[12]
[13], whereby direct clipping involves capturing the vessel directly and indirect clipping
involves closing the diverticular orifice in a zipper-like manner [9]
[10]. A large multicenter cohort study in Japan found that the rebleeding rate was significantly
lower after direct clipping than after indirect clipping [14]. However, direct clipping for CDB with active bleeding is challenging and is reported
to be less effective because the bleeding point is obscured by blood [14].
Recently, endoscopic band ligation (EBL) has been used for CDB because it is reported
to have higher efficacy compared with clipping [8]
[15]
[16]. For example, a large multicenter cohort study in Japan found that the rebleeding
rate was significantly lower after EBL than after clipping and that the results were
unchanged in the subgroup of CDB with active bleeding [16]. However, EBL has disadvantages in that the endoscope requires reinsertion for attachment
of a ligation device and is associated with a risk of delayed perforation [17]
[18]
[19].
Based on these results, when direct clip placement at the bleeding point is feasible
(e.g., non-active bleeding), direct clipping as the first choice for endoscopic hemostasis
is expected to be effective in preventing rebleeding and shorter and safer than EBL.
Moreover, EBL as the second choice is expected to be more effective than direct clipping
in cases where accurate direct clip placement at the bleeding point is difficult (e.g.,
active bleeding). If clipping or EBL for CDB can be appropriately selected, we can
realize the advantages of both strategies, thereby improving clinical outcomes. However,
no studies have evaluated the usefulness of a treatment selection strategy for clipping
and EBL in CDB. We hypothesized that direct clipping, which entails precise grasping
of the bleeding point of CDB, would be as effective as EBL and subsequently developed
the following treatment selection strategy in 2016 when we introduced EBL. At our
institution, direct clipping is the first choice if the bleeding point is visible
and direct endoclip placement at the bleeding point is possible; if direct clipping
is not feasible, EBL is the second choice. In this study, we evaluated the effectiveness
of our treatment selection strategy for endoscopic hemostasis in patients with definitive
CDB.
Patients and methods
Patients and study design
We retrospectively reviewed the electronic admission and endoscopy databases at Nara
City Hospital and identified 391 adult patients who were emergently hospitalized for
acute hematochezia between March 2016 and February 2023. Of the 205 patients diagnosed
with definitive CDB based on presence of SRH, we analyzed data from 192 patients who
were successfully treated by clipping (n=84) or EBL (n=108), ([Fig. 1]). The study protocol was approved by the ethics committee and institutional review
board of Nara City Hospital.
Fig. 1 Flowchart showing the patient selection process.
Endoscopic procedures and strategy for endoscopic hemostasis (with video)
All patients in this study received standard supportive medical care for acute lower
gastrointestinal bleeding, including hemodynamic monitoring and fluid resuscitation.
Packed red blood cells were transfused to correct severe anemia if necessary. Bowel
preparation with polyethylene glycol or glycerin enema was performed before colonoscopy
if possible. All patients underwent colonoscopy with a distal attachment cap and a
water-jet device (OFP-2; Olympus Corp., Tokyo, Japan). The most commonly used colonoscope
was the PCF-Q260AZI (Olympus Corp.). Colonic diverticula were observed under water
immersion to improve endoscopic visualization [20] ([Video 1]: Case 1–3).
Endoscopic hemostasis for colonic diverticular bleeding.
Case 1. Direct clipping for colonic diverticular bleeding under water observation.
Case 2. Endoscopic band ligation for active colonic diverticular bleeding.
Case 3. Direct clipping for active colonic diverticular bleeding using a clip device
with a re-grasping function.* (*Note: This case was outside the study period.)Video
1
When SRH was identified, we observed the bleeding point and selected the treatment
method according to how easily the bleeding point could be visualized and maneuverability
of the colonoscope. In principle, the treatment selection policy at our institution
is as follows. If the bleeding point is visible and an endoclip insertion is possible,
direct clipping is selected as the first choice ([Video 1]: Case 1). If direct clipping is not feasible, EBL is selected as the second choice
([Video 1]: Case 2). If both direct clipping and EBL are difficult, indirect clipping is selected
as the third choice. Final treatment selection is made at the discretion of the endoscopist
depending on patient comorbidities, ease of insertion of the endoscope, and maneuverability.
If initial endoscopic hemostasis fails, additional endoscopic treatment is performed
if possible. In this study, patient outcomes were evaluated according to the method
that ultimately achieved successful hemostasis ([Fig. 2]).
Fig. 2 Clinical course of endoscopic hemostasis.
When using the direct clipping method, endoclips (HX-610–090S EZ CLIP; Olympus Corp.)
are placed directly on the vessel [12]
[13] ([Fig. 3]
a, [Fig. 3]
b). When using the indirect clipping method, the diverticulum is closed in a zipper-like
manner [12]
[13] ([Fig. 3]
c, [Fig. 3]
d). The EBL method for CDB is the same as that reported previously [15]
[21]. After the site of bleeding has been marked with endoclips, the colonoscope is removed
and then reinserted after attachment of a band ligator device (MD-48912B EBL; Sumitomo
Bakelite Company Ltd., Tokyo, Japan). The diverticulum is then pulled into the cup
of the endoscopic ligator by suction, and the elastic O-ring is released ([Fig. 3]
e, [Fig. 3]
f).
Fig. 3 Endoscopic findings. a Colonic diverticulum with a visible non-bleeding vessel. b
After direct clip placement. c Active bleeding from the colonic diverticulum. d The
diverticulum was closed in a zipper-like manner via indirect clip placement. e Colonic
diverticulum with an adherent clot. f After endoscopic band ligation.
Variables investigated
We assessed the clinical data, including baseline characteristics such as age, sex,
vital signs on admission, and lifestyle factors as well as presenting symptoms, laboratory
data, comorbidities, and medication use. We also reviewed in-hospital examination
findings obtained from electronic medical records and endoscopy databases. Comorbidities
were assessed using the Charlson Comorbidity Index
[22]
with the addition of the following four items: hypertension, diabetes mellitus, dyslipidemia,
and cerebrovascular or cardiovascular disease. We also evaluated items concerning
endoscopic procedures, including type of bowel preparation, use of a distal attachment
cap, use of a water-jet device, type and location of SRH, bleeding point in the diverticulum,
method of endoscopic hemostasis, and procedure time. SRH was defined as active or
non-active bleeding (a densely adherent clot despite vigorous irrigation and/or a
visible non-bleeding vessel) seen on colonoscopy [4]
[12] ([Fig. 3]
a, [Fig. 3]
c, [Fig. 3]
e). SRH was classified as left-sided (descending colon, sigmoid colon, and rectum)
or right-sided (other locations).
Outcomes
The outcome of interest was rebleeding after endoscopic treatment during hospitalization
or after discharge. Early rebleeding was defined as rebleeding within 30 days of endoscopic
treatment for CDB and late rebleeding as rebleeding within 1 year [12]
[23]. Secondary outcomes were need for IVR or surgery after endoscopic treatment, blood
transfusion requirement during hospitalization, length of hospital stay, and endoscopy-related
outcomes, including type of SRH, bleeding point in the diverticulum, location of SRH,
success rate of initial endoscopic hemostasis, and procedure time.
Statistical analysis
Patient characteristics and outcomes were compared between the clipping and EBL groups.
Categorical data were compared between the two treatment groups using the chi-squared
test or Fisher’s exact test, as appropriate. Continuous data were compared using the
Mann-Whitney U test. Propensity score matching (PSM) was used to adjust for differences between
the two treatment groups. A logistic regression model was used for propensity score
estimation, with EBL as a function of patient baseline characteristics and endoscopic
factors. The model included age ≥70 years, sex, and seven factors found to be of at
least borderline significance (P <0.10) in univariate analysis ([Table 1]). We performed one-to-one PSM between the clipping and EBL groups, using the nearest
neighbor method within a caliper width of 0.2 of the standard deviation of the logit
of the propensity score. Before matching, the area under the receiver-operating characteristic
curve for propensity scores was 0.734 (95% confidence interval [CI] 0.664–0.803) for
EBL. Time-to-event analysis was performed using the Kaplan-Meier method and log-rank
test. Statistical analysis was performed using Statistical Package for Social Sciences
version 22 (IBM Corp., Armonk, New York, United States). P <0.05 was considered statistically significant.
Table 1 Patient characteristics in the total population and propensity score-matched population
according to whether definitive colonic diverticular bleeding was treated by clipping
or endoscopic band ligation.
|
Unmatched cohort (N=192)
|
Matched cohort (N=132)
|
|
Clipping (n=84)
|
Band ligation (n=108)
|
ASD
|
P value
|
Clipping (n=66)
|
Band ligation (n=66)
|
ASD
|
P value
|
Data are shown as the number (percentage) or median (interquartile range). Bold type
indicates P <0.05. A logistic regression model was used to estimate the propensity score. The
model included age ≥70 years, sex, and factors found to be of at least borderline
significance (<0.10) in univariate analysis (history of colorectal surgery, Charlson
Comorbidity Index ≥2, diabetes mellitus, cerebrovascular or cardiovascular disease,
anticoagulant therapy, hemoglobin ≤12 g/dL, and extravasation on CT).
*Antiplatelet drugs included low-dose aspirin, thienopyridine, cilostazol, and others.
†Anticoagulants included warfarin and direct oral anticoagulants.
ASD, absolute standardized difference; CT, computed tomography; PT-INR, prothrombin
time-international normalized ratio; NA, not applicable; NSAID, nonsteroidal anti-inflammatory
drug; PEG, polyethylene glycol.
|
Direct clipping
|
78 (92.9)
|
|
|
|
61 (92.4)
|
|
|
|
Age ≥70 years
|
56 (66.7)
|
67 (62.0)
|
0.102
|
0.507
|
41 (62.1)
|
39 (59.1)
|
0.112
|
0.722
|
Sex (male)
|
54 (64.3)
|
61 (56.5)
|
0.141
|
0.274
|
37 (56.1)
|
39 (59.1)
|
0.113
|
0.725
|
Body mass index ≥25
|
25 (32.1)
|
32 (31.1)
|
0.163
|
0.888
|
24 (38.1)
|
19 (31.1)
|
0.101
|
0.416
|
Current drinker
|
39 (50.0)
|
42 (45.2)
|
0.02
|
0.528
|
29 (47.5)
|
26 (46.4)
|
0.37
|
0.904
|
Current smoker
|
12 (15.4)
|
12 (12.5)
|
0.16
|
0.583
|
10 (16.4)
|
9 (15.3)
|
0.064
|
0.864
|
Performance status ≥2
|
8 (9.5)
|
7 (6.5)
|
0.138
|
0.436
|
5 (7.6)
|
3 (4.5)
|
0.031
|
0.718
|
Comorbidities
|
|
0 (0)
|
7 (6.5)
|
0.348
|
0.019
|
0 (0)
|
0 (0)
|
NA
|
NA
|
|
42 (50.0)
|
58 (53.7)
|
0.478
|
0.610
|
35 (53.0)
|
36 (54.5)
|
0.021
|
0.861
|
|
11 (13.1)
|
28 (25.9)
|
0.425
|
0.028
|
10 (15.2)
|
12 (18.2)
|
0.123
|
0.64
|
|
48 (57.1)
|
66 (61.1)
|
0.179
|
0.579
|
42 (63.6)
|
38 (57.6)
|
0.077
|
0.476
|
|
7 (8.3)
|
21 (19.4)
|
0.403
|
0.030
|
7 (10.6)
|
10 (15.2)
|
0.189
|
0.436
|
|
17 (20.2)
|
26 (24.1)
|
0.085
|
0.527
|
16 (24.2)
|
14 (21.2)
|
0.083
|
0.678
|
|
21 (25.0)
|
41 (38.0)
|
0.438
|
0.057
|
21 (31.8)
|
17 (25.8)
|
0.025
|
0.442
|
Loss of consciousness
|
8 (9.5)
|
6 (5.6)
|
0.229
|
0.294
|
7 (10.6)
|
4 (6.1)
|
0.216
|
0.345
|
Systolic blood pressure ≤100 mmHg
|
9 (10.7)
|
11 (10.2)
|
0.061
|
0.905
|
9 (13.6)
|
8 (12.1)
|
0.156
|
0.795
|
Pulse ≥100 bpm
|
19 (22.6)
|
21 (19.4)
|
0.096
|
0.591
|
15 (22.7)
|
10 (15.2)
|
0.094
|
0.267
|
Medication
|
|
11 (13.1)
|
17 (15.7)
|
0.029
|
0.606
|
8 (12.1)
|
9 (13.6)
|
0.094
|
0.795
|
|
22 (26.2)
|
32 (29.6)
|
0.163
|
0.599
|
20 (30.3)
|
20 (30.3)
|
0.044
|
1
|
|
7 (8.3)
|
21 (19.4)
|
0.334
|
0.030
|
6 (9.1)
|
6 (9.1)
|
0.043
|
1
|
|
3 (3.6)
|
3 (2.8)
|
0.115
|
1.000
|
2 (3.0)
|
0 (0)
|
0.298
|
0.496
|
Initial laboratory data
|
|
43 (51.2)
|
41 (38.0)
|
0.309
|
0.067
|
30 (45.5)
|
30 (45.5)
|
0.013
|
1
|
|
12 (14.3)
|
9 (8.3)
|
0.269
|
0.190
|
10 (15.2)
|
5 (7.6)
|
0.396
|
0.17
|
|
14 (16.7)
|
10 (9.3)
|
0.209
|
0.124
|
10 (15.2)
|
5 (7.6)
|
0.28
|
0.17
|
|
3 (3.7)
|
2 (2.0)
|
0.265
|
0.658
|
1 (1.6)
|
2 (3.3)
|
0.209
|
0.616
|
|
15 (18.3)
|
12 (11.1)
|
0.066
|
0.160
|
11 (17.2)
|
7 (10.6)
|
0.094
|
0.277
|
|
3 (4.3)
|
7 (7.9)
|
0.168
|
0.514
|
3 (5.6)
|
3 (5.7)
|
0.101
|
1
|
Extravasation on CT
|
2 (2.4)
|
13 (12.0)
|
0.478
|
0.013
|
2 (3.0)
|
1 (1.5)
|
0.021
|
1
|
Colonoscopy-associated factors
|
|
82 (97.6)
|
99 (91.7)
|
0.359
|
0.117
|
64 (97.0)
|
63 (95.5)
|
0.247
|
1
|
|
79 (94.0)
|
91 (84.3)
|
–
|
0.035
|
63 (95.5)
|
59 (89.4)
|
–
|
0.188
|
|
3 (3.6)
|
8 (7.4)
|
–
|
0.353
|
1 (1.5)
|
4 (6.1)
|
–
|
0.365
|
Time from presentation to colonoscopy, h
|
6 (4–7)
|
5 (3–6)
|
–
|
0.004
|
5.5 (4–7)
|
5 (4–7)
|
–
|
0.257
|
Early colonoscopy (<24 h of presentation)
|
80 (95.2)
|
103 (95.4)
|
0.129
|
1
|
65 (98.5)
|
63 (95.5)
|
NA
|
0.619
|
Non-early colonoscopy (>24 h after presentation)
|
4 (4.8)
|
5 (4.6)
|
–
|
1
|
1 (1.5)
|
3 (4.5)
|
–
|
0.619
|
Use of endoscopic distal attachment cap
|
84 (100)
|
108 (100)
|
NA
|
NA
|
66 (100)
|
66 (100)
|
NA
|
NA
|
Use of a water-jet device
|
84 (100)
|
108 (100)
|
NA
|
NA
|
66 (100)
|
66 (100)
|
NA
|
NA
|
Results
Patient characteristics
Baseline characteristics of the 192 patients who underwent clipping or EBL for definitive
CDB are shown in Supplementary Table 1. The hemostatic method was clipping in 84 patients
(direct, n=78; indirect, n=6) and EBL in 108. Baseline characteristics of the unmatched
and matched cohorts are presented in [Table 1]. In the unmatched cohort, the clipping and EBL groups showed significant differences
(P <0.05) in five variables at baseline, with an absolute standardized difference (ASD)
>0.2 for 13 variables. PSM identified 132 patients, comprising 66 pairs from the clipping
and EBL groups. The number of variables with an ASD >0.2 was reduced to seven, and
baseline characteristics were more balanced in the PSM data.
Endoscopy-related outcomes in our treatment selection strategy
In the unmatched cohort, clipping was selected significantly more frequently than
EBL for visible vessels, bleeding at the dome of the diverticulum, and a right-sided
diverticulum. However, EBL was selected significantly more frequently than clipping
for active bleeding, unconfirmed bleeding point, and for bleeding in the left side
of the colon. Total procedure time and time to hemostasis after identification of
the SRH was significantly shorter in the clipping group than in the EBL group. These
results did not change in the matched cohorts, except for the location of SRH ([Table 2]). Success rates of initial endoscopic hemostasis in direct clipping, indirect clipping,
and EBL were 86.4% (76/88), 100% (4/4), and 92.4% (97/105), respectively ([Fig. 2]).
Table 2 Endoscopy-related outcomes in our treatment selection strategy.*
|
Unmatched cohort (N=192)
|
Matched cohort (N=132)
|
|
Clipping (n=84)
|
Band ligation (n=108)
|
P value
|
Clipping (n=66)
|
Band ligation (n=66)
|
P value
|
Data are shown as the number (percentage) or median (interquartile range). Bold values
indicate P <0.05.
*The treatment selection policy at our institution is as follows. If the bleeding
point is visible and an endoclip insertion is possible, direct clipping is selected
as the first choice ([Video 1]
: Case 1). If direct clipping is not feasible, band ligation is selected as the second choice
([Video 1]
: Case 2). If both direct clipping and band ligation are difficult, indirect clipping is selected
as the third choice.
†Total procedure time was defined as total time from the start to end of colonoscopy.
SRH, stigmata of recent hemorrhage.
|
SRH-related outcomes
|
|
|
28 (33.3)
|
65 (60.2)
|
<0.001
|
23 (34.8)
|
35 (53.0)
|
0.035
|
|
43 (51.2)
|
24 (22.2)
|
<0.001
|
35 (53.0)
|
16 (24.2)
|
0.001
|
|
13 (15.5)
|
19 (17.6)
|
0.696
|
8 (12.1)
|
15 (22.7)
|
0.108
|
|
|
62 (73.8)
|
36 (33.3)
|
<0.001
|
48 (72.7)
|
23 (34.8)
|
<0.001
|
|
6 (7.1)
|
4 (3.7)
|
0.338
|
5 (7.6)
|
(6.1)
|
1
|
|
16 (19.0)
|
68 (63.0)
|
<0.001
|
13 (19.7)
|
39 (59.1)
|
<0.001
|
|
|
68 (81.0)
|
73 (67.6)
|
0.038
|
53 (80.3)
|
50 (75.8)
|
0.528
|
|
16 (19.0)
|
35 (32.4)
|
0.038
|
13 (19.7)
|
16 (24.2)
|
0.528
|
Total procedural time,† min
|
42.5 (29–62)
|
63.5 (47–78)
|
<0.001
|
45.5 (29–62)
|
66 (47–84)
|
<0.001
|
Time to hemostasis after identification of SRH, min
|
9 (6–14.5)
|
22 (14–31.5)
|
<0.001
|
9 (6–14)
|
21.5 (14–34)
|
<0.001
|
Clinical outcomes of clipping and EBL in our treatment selection strategy
In the unmatched cohort, there was no significant differences in early or late rebleeding
rate between clipping and EBL (15.5% vs. 13.0%, P=0.619 and 28.6% vs. 27.8%, P=0.903, respectively). Furthermore, there were no significant between-group differences
in need for IVR, need for surgery, or length of hospital stay. These results were
unchanged in the matched cohort ([Table 3]). Kaplan-Meier analysis revealed no significant difference in likelihood of rebleeding
between the two groups during a mean follow-up of 284 days (P=0.938, log-rank test) (Supplementary Fig. 1).
Table 3 Clinical outcomes of clipping and band ligation in our treatment selection strategy.*
|
Unmatched cohort (N=192)
|
Matched cohort (n=132)
|
|
Clipping (n=84)
|
Band ligation (n=108)
|
Crude OR (95% CI)
|
P value
|
Clipping (n=66)
|
Band ligation (n=66)
|
Crude OR (95% CI)
|
P value
|
Data are shown as the number (percentage) or median (interquartile range).
*Treatment selection policy at our institution is as follows. If the bleeding point
is visible and endoclip insertion is possible, direct clipping is selected as the
first choice ([Video 1]
: Case 1). If direct clipping is not feasible, band ligation is selected as the second choice
([Video 1]
: Case 2). If both direct clipping and band ligation are difficult, indirect clipping is selected
as the third choice.
CI, confidence interval; IVR, interventional radiology; NA, not applicable; OR, odds
ratio.
|
Rebleeding within 30 days after endoscopic treatment
|
13 (15.5)
|
14 (13.0)
|
0.813 (0.360–1.838)
|
0.619
|
10 (15.2)
|
10 (15.2)
|
1 (0.386–2.590)
|
1
|
Rebleeding within 1 year after endoscopic treatment
|
24 (28.6)
|
30 (27.8)
|
0.962 (0.510–1.812)
|
0.903
|
21 (31.8)
|
20 (30.3)
|
0.932 (0.446–1.948)
|
0.851
|
IVR needed after endoscopic treatment
|
1 (1.2)
|
1 (0.9)
|
0.776 (0.048–12.59)
|
1.000
|
1 (1.5)
|
0 (0)
|
NA
|
1
|
Surgery needed after endoscopic treatment
|
0 (0)
|
1 (0.9)
|
NA
|
1.000
|
0 (0)
|
0 (0)
|
NA
|
NA
|
Blood transfusion requirement during hospitalization
|
18 (21.4)
|
14 (13.0)
|
0.546 (0.254–1.175)
|
0.118
|
14 (21.2)
|
10 (15.2)
|
0.663 (0.271–1.623)
|
0.367
|
Length of hospital stay, days
|
6 (4–8.5)
|
5 (4–8)
|
NA
|
0.079
|
6 (4–9)
|
5.5 (4–8)
|
NA
|
0.593
|
Prolonged hospitalization (≥7 days)
|
38 (45.2)
|
41 (38.0)
|
0.741 (0.415–1.322)
|
0.310
|
31 (47.0)
|
30 (45.5)
|
0.941 (0.475–1.865)
|
0.861
|
Characteristics of patients who underwent endoscopic hemostasis for definitive CDB
according to rebleeding status
Baseline characteristics of the rebleeding and non-rebleeding patients who underwent
clipping are presented in Supplementary Table 2. Significant differences in current
alcohol consumption and type of SRH (active bleeding) were found between the rebleeding
and non-bleeding groups. Baseline characteristics in the rebleeding and non-rebleeding
patients who underwent EBL are compared in Supplementary Table 3. Significant differences
were found between the rebleeding and non-bleeding groups according to whether or
not body mass index was ≥25.
Endoscopically relevant adverse events
No endoscopically relevant adverse events (AEs) were observed after clipping. However
colonic diverticulitis and perforation developed in one patient (0.93%) following
EBL. The patient was a 63-year-old man who presented to our hospital with massive
hematochezia. He was taking prednisolone 30 mg and tocilizumab for adult-onset Still’s
disease and rivaroxaban for paroxysmal atrial fibrillation. Contrast-enhanced computed
tomography (CT) revealed two extravasation sites, one in the sigmoid colon and the
other in the descending colon. Emergency colonoscopy showed a diverticulum with an
adherent clot in the descending colon but no SRH in the sigmoid colon. EBL was performed
for the SRH in the descending colon. No rebleeding was observed after EBL, and the
patient was discharged 5 days after treatment. On Day 14 after EBL, the patient was
readmitted to our hospital with left lower abdominal pain. Sigmoid colon diverticulitis
was diagnosed based on CT and was treated with antibiotics. On Day 19 after EBL, the
patient developed severe lower abdominal pain, and colon perforation was diagnosed
by CT. Emergency surgery revealed two perforation sites, one in the sigmoid colon
and the other in the descending colon. Colonic resection and colostomy were performed.
Discussion
To our knowledge, this is the first study to evaluate the validity of a selection
strategy for endoscopic hemostatic methods in CDB according to endoscopic findings
for the bleeding point. The main result was that there was no significant difference
in terms of bleeding rate (within 30 days or 1 year), need for IVR or surgery, blood
transfusion requirement, or length of hospital stay between the clipping group and
the EBL group when direct clipping was selected when feasible. Other important findings
of this study are as follows. First, unlike in previous studies (Supplementary Table
4), the proportion of patients who underwent direct clipping was high in the overall
population as well in the clipping group at 40.6% (78/192) and 92.9% (78/84), respectively.
Second, EBL was selected significantly more often for CDB with active bleeding and
in the left side of the colon. Third, total procedure time was significantly shorter
for the clipping group than for EBL. Fourth, delayed perforation was observed in the
EBL group but there were no complications in the clipping group. These findings suggest
that the strategy of direct clipping when clip placement at the bleeding point is
feasible and EBL when direct clipping is not feasible is reasonable in terms of effectiveness,
efficiency, and safety of treatment. Importantly, the cases completed with direct
clipping alone when feasible did not negatively affect outcomes. In fact, those cases
showed benefits such as reduced procedure time. Also, the extended procedure time
with EBL did not compromise clinical outcomes.
Direct clipping was selected for cases in which the view of the bleeding point and
endoscopic maneuverability were sufficient to allow direct clip placement at the bleeding
point, whereas indirect clipping was rarely selected. Our treatment selection strategy
for clipping methods was considered to make clipping more effective and to be the
reason why there was no significant difference in rebleeding rate between clipping
and EBL. Direct clipping achieves hemostasis by grasping the bleeding point, whereas
indirect clipping achieves hemostasis by closing the diverticulum and compressing
it with a hematoma. Previous studies have reported that the rebleeding rate is higher
with indirect clipping than with direct clipping [13]
[14], suggesting that the hemostatic effect of clipping is more effective when the bleeding
point is directly grasped. Interestingly, we found no significant difference in early
or late rebleeding rates between the clipping and EBL groups. We speculated that this
may be because direct clipping blocks blood flow in the vessel, ultimately causing
the vessel to disappear. However, the late rebleeding rate was high in both the clipping
group (28.6%) and the EBL group (27.8%) in our study, possibly because the rebleeding
sites were different from the previously treated sites, as reported previously [12].
We reviewed previous studies investigating the effectiveness of endoscopic clipping
and EBL for CDB (Supplementary Table 4) and found a mean early rebleeding rate of
12.3% (186/1512) for EBL, which is similar to our rate of 13.0%. However, the mean
early rebleeding rate after clipping was 24.3% (462/1901), which is higher than our
rate of 15.5%. It is also noteworthy that the proportion of direct clipping procedures
was much higher (92.9%, 78/84) in our study than in previous reports, suggesting that
rebleeding after clipping depends on how accurately the clip is placed at the bleeding
point.
However, hemostasis with direct clipping may be difficult [21]
[24]. Direct clip placement in colonic diverticula may be affected by how endoscopic
observation is performed, ease of endoclip insertion, and stability of the endoscope.
We attempted to overcome these issues by using underwater observation with a distal
attachment cap and a water-jet device [13]
[20]. As a result, the proportion of cases in which direct clipping was performed was
40.6% (78/192), which is higher than the 21.4% (360/1679) found in a retrospective
analysis of a large multicenter cohort of Japanese patients with definitive CDB
[14]
[16]
. Endoscopic images and video depictions of direct clipping for CDB using underwater
observation are available in a recently published series [13]
[25]
[26].
In our study, rebleeding after clipping was significantly more common in patients
with active bleeding during the procedure. We speculated that this may be because
active bleeding obscures the bleeding point, making it difficult to accurately grasp
the bleeding point for direct clipping. Other studies have also found an association
between clipping under conditions with poor visibility, such as active bleeding, and
rebleeding [14]
[27]. A recently developed novel clip device with a re-grasping function (SureClip; Micro-Tech
Co., Nanjing, China) has two advantages. First, the clip can be opened inside the
diverticulum and grasp the base of the diverticulum, even if the diverticular orifice
is small. Second, grasping can be repeated until hemostasis is confirmed, even if
the bleeding point is not visible because of, for example, active bleeding [28]. Direct clipping might be feasible using this device even in active CDB (Video:
Case 3). In contrast, no association was found between active bleeding in EBL and
rebleeding (Supplementary Table 3). We found EBL to be effective even in patients
with active bleeding during EBL, which is consistent with a previous report [16]. A Japanese study based on the Nationwide ALGIB endoscopy dataset [29] found that the 30-day rebleeding rate was significantly higher after direct clipping
than after snare or band ligation in right-sided CDB with active bleeding. However,
the investigators found no significant difference in 30-day rebleeding rate between
ligation and direct clipping in right-sided CDB without active bleeding. These results
are in line with our present findings. Therefore, a ligation method such as EBL should
be chosen when accurate direct clipping is difficult because of active bleeding.
In our patients, EBL was selected significantly more often for the left side of the
colon. Compared with the right side, the left side has a narrower lumen and stronger
flexion [30], which reduces the maneuverability of the scope and the visual field [31]. Direct clipping is difficult when scope maneuverability is poor and the field of
view is limited. Analysis of the Nationwide ALGIB endoscopy dataset in Japan revealed
no association between the 30-day rebleeding rate and the method used for hemostasis
(i.e., ligation, direct clipping, or indirect clipping) in left-sided CDB, regardless
of active bleeding [29]. However, in view of the potential AEs discussed below, it is reasonable to select
direct clipping for the left side of the colon if technically feasible.
EBL can achieve hemostasis even in active CDB, but the procedure time is longer than
that with clipping. One case of delayed perforation was observed in our study. In
the previously mentioned Japanese study based on the Nationwide ALGIB endoscopy dataset,
all cases of delayed perforation occurred after EBL for left-sided CDB
[29]
. Furthermore, colonic diverticulitis occurred after endoscopic ligation and indirect
clipping, but not after direct clipping. Frequency of delayed perforation after EBL
has been reported to be as low as 0.31% (2/638)
[16]
, but all such cases required surgical intervention [17]
[18]
[19]. Our patient with delayed perforation had perforations at two sites, making it less
likely that EBL was the direct cause of the perforation and raising the possibility
that medications (prednisolone and tocilizumab) for collagen disease were associated
with the perforation [32]
[33]. However, when performing endoscopic hemostasis for CDB in patients at high risk
of delayed perforation (e.g., those on high-dose steroids [19] or tocilizumab [32]
[33]), it may be preferable to choose a treatment modality with a low risk of perforation,
such as clipping or injection of a self-assembling peptide material (PuraStat; 3-D
Matrix, Tokyo, Japan)
[34]
. Frequency of diverticulitis after indirect clipping has been reported to be as low
as 0.7%
[29]
, but it is important to consider. We speculate that complete closure of the diverticulum
by indirect clipping increases pressure in the diverticulum, which increases risk
of bacteremia [35] and diverticulitis. Therefore, from the point of view of AEs, direct clipping should
be chosen when clipping is performed.
This study has some limitations. First, it had a retrospective, single-center design
and was performed in a Japanese population, so selection bias cannot be excluded.
Moreover, although patient characteristics were balanced by PSM, endoscopic findings
of SRH differed between the clipping and EBL groups because the hemostatic method
was determined based on endoscopic findings at the bleeding point. Therefore, the
effectiveness of clipping and EBL could not be directly compared in this study. Multicenter,
prospective studies are needed to validate our findings. The study also has some strengths,
in that we collected detailed information about, for example, endoscopic findings
(e.g., type and location of SRH) and extravasation on CT as well as long-term follow-up
data. Moreover, there were few missing values in the data collected.
Conclusions
In conclusion, our results suggest that the endoscopic method for hemostasis in cases
of CDB should be determined based on maneuverability of the endoscope, visibility
at the bleeding point, and risk of complications. If direct clip placement for the
bleeding point is feasible, selection of direct clipping is acceptable. The strategy
of selecting clipping or EBL according to visibility at the bleeding point and maneuverability
of the endoscope is reasonable in terms of effectiveness, efficiency, and safety of
treatment.
Correction: Useful treatment selection strategy for endoscopic hemostasis in colonic
diverticular bleeding according to endoscopic findings (with video)
Correction: Useful treatment selection strategy for endoscopic hemostasis in colonic
diverticular bleeding according to endoscopic findings (with video)
In the above-mentioned article Figure 2 was corrected.
This was corrected in the online version on 02.04.2025.
Bibliographical Record
Takaaki Kishino, Yoko Kitamura, Takashi Okuda, Naoki Okamoto, Takayuki Sawa, Maiko
Yamakawa, Kazuyuki Kanemasa. Useful treatment selection strategy for endoscopic hemostasis
in colonic diverticular bleeding according to endoscopic findings (with video). Endosc
Int Open 2025; 13: a24711016.
DOI: 10.1055/a-2471-1016